AVOID SIMULTANEUS PRESCRIPTION BETWEEN LINEZOLID AND VORICONAZOL: PHARMACOKINETIC STUDY



Idoate Grijalba AI, Leache Alegría L, Aldaz Pastor A Pharmacy Department. University Clinic of Navarra. Pamplona.

Introduction

Take linezolid (LIN) and voriconazole (VCZ) at same time is common in routine clinical practice.


Voriconazole (VCZ): Hepatic metabolism. Isoforms CYP2C19, CYP3A4 and CYP2C9.

Linezolid (LIN): Metabolized in two metabolites (65%). Main metabolite independent of cytochrome P-450-isoenzymes

Objetive: Analyze the potential of interaction between LIN and VCZ by pharmacokinetic monitoring.

Material y Methods

- Single-centre, retrospective and observational study.
- Patients under simultaneous treatment with LIN and VCZ between March-2009 to December-2015



2 Liquid chromatography (HPLC)



After at least 3 days of combined therapy.



Oral apparent VCZ clearance (CL/F L/h) was estimated

- Before treatment with LIN (CL/Fb)
- During LIN treatment (CL/Fd LIN)

<u>Variables</u>


- ✓ Demographic: age, sex
- Treatment: dosing schedule, date and time of each dose.
- ✓ Clinic: diagnosis, microbiological information, etc.
- ✓ Kinetics: date and time of each sample.

Therapeutic range of VCZ

Candida spp.: 1.5 – 4.5 mcg/mL Aspergillus spp.: 2 – 4.5 mcg/mL

Results

Variable	Result (n=5)
Sex (men %)	100%
Age (years), median (range)	67(57-73)
Dose/day LIN (mg)	1.200
Dose/day VCZ (mg), mean ± SD	454.5±157.2
CL/Fb (L/h)	2.7±0.8
CL/Fd LIN (L/h)	22.1±11.7



Probable Interaction VCZ -LIN

80% (n=4)
Infra-therapeutic VCZ concentrations

20% (n=1) Ultrarrapid metabolizer (CYP2C19*27*27) had infra-therapeutic concentrations before combined therapy VCZ-LIN

222

2

3

change anti-infective treatment to vancomycin or daptomycin.

Maintained linezolid and increase VCZ dose up to 75% to reach at least the lower

limit of therapeutic range.

Conclusion

VCZ concentrations observed (mcg/ mL): 0.9, 0.93, 0.42, 1.13, 1.21 VCZ concentrations target (mcg/mL): 2-5

- ✓ Add LIN to VCZ treatment **increases VCZ clearance** between 250-700% and as a result, plasma antifungical concentrations decrease with a significant clinical effect. This translates into a loss of effectiveness in antifungical treatment in 80% of cases.
- ✓ The use of this combination is contraindicated and if clinically there is no other alternative, VCZ pharmacokinetic monitoring is recommended to ensure effectiveness of antifungical treatment.